Kelly S. Chien

Hematology

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 106 publications

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.

Journal: American journal of hematology

Published: May 14, 2026

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica

Published: April 22, 2026

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Journal: Journal of hematology & oncology

Published: April 17, 2026

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Journal: Leukemia & lymphoma

Published: March 30, 2026

Aberrant oxidative metabolism selects for TET2 -deficient hematopoietic stem and progenitor cells.

Aberrant oxidative metabolism selects for TET2 -deficient hematopoietic stem and progenitor cells.

Journal: bioRxiv : the preprint server for biology

Published: March 23, 2026

Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation.

Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation.

Journal: Haematologica

Published: March 10, 2026

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 09, 2026

The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat.

The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat.

Journal: Haematologica

Published: February 11, 2026

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

Journal: American journal of hematology

Published: February 09, 2026

Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.

Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: February 02, 2026

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Journal: Leukemia

Published: December 10, 2025

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.

Journal: Blood cancer journal

Published: December 04, 2025

Showing 1-12 of 106

Last Updated: 09/26/2026